Cytarabine
Nodal Marginal Zone B-Cell Lymphoma
Explore 35 assets in Nodal Marginal Zone B-Cell Lymphoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Izidore Lossos, MD
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06796998CT.gov Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) | — | Recruiting | — | — | — |
NCT06905509CT.gov Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT01769911CT.gov Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nodal Marginal Zone B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cytarabine (this asset) | Izidore Lossos, MD | P2 | CCC · 53 |
| Cyclophosphamide | SWOG Cancer Research Network | P2 | BB |
| Etoposide | University of California, Davis | P2 | BB |
| Fludarabine | UNC Lineberger Comprehensive Cancer Center | P2 | BB |
| Dexasone | Izidore Lossos, MD | P2 | BB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BB |
| Romidepsin | Mayo Clinic | P2 | BB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Irinotecan | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Nodal Marginal Zone B-Cell Lymphoma cohort
Other indications for Cytarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Acute Myeloblastic Leukemia With Maturation | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cytarabine in Nodal Marginal Zone B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cytarabine-nodal-marginal-zone-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →